SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062034
Filing Date
2023-11-09
Accepted
2023-11-09 16:09:41
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20231109.htm   iXBRL 8-K 52813
2 EX-99.1 dnth-ex99_1.htm EX-99.1 220309
  Complete submission text file 0000950170-23-062034.txt   449411

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnth-20231109_def.xml EX-101.DEF 15092
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnth-20231109_pre.xml EX-101.PRE 15363
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnth-20231109.xsd EX-101.SCH 3375
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnth-20231109_lab.xml EX-101.LAB 24652
8 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20231109_htm.xml XML 4876
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 231392442
SIC: 2834 Pharmaceutical Preparations